Last reviewed · How we verify
Desvenlafaxine Succinate Sustained-Release Formulation 50 mg
Desvenlafaxine Succinate Sustained-Release Formulation 50 mg is a Small molecule drug developed by Pfizer. It is currently FDA-approved.
At a glance
| Generic name | Desvenlafaxine Succinate Sustained-Release Formulation 50 mg |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desvenlafaxine Succinate Sustained-Release Formulation 50 mg CI brief — competitive landscape report
- Desvenlafaxine Succinate Sustained-Release Formulation 50 mg updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Desvenlafaxine Succinate Sustained-Release Formulation 50 mg
What is Desvenlafaxine Succinate Sustained-Release Formulation 50 mg?
Desvenlafaxine Succinate Sustained-Release Formulation 50 mg is a Small molecule drug developed by Pfizer.
Who makes Desvenlafaxine Succinate Sustained-Release Formulation 50 mg?
Desvenlafaxine Succinate Sustained-Release Formulation 50 mg is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What development phase is Desvenlafaxine Succinate Sustained-Release Formulation 50 mg in?
Desvenlafaxine Succinate Sustained-Release Formulation 50 mg is FDA-approved (marketed).